FOXN2 Activators
FOXN2 Activators encompass a range of compounds that influence various intracellular signaling cascades, each potentially enhancing the functional activity of FOXN2 through indirect mechanisms. Forskolin raises intracellular cAMP levels, leading to PKA activation, which is known to phosphorylate transcription factors in the FOX family, suggesting a similar influence on FOXN2. IBMX maintains elevated cAMP levels, again pointing to enhanced FOXN2 activity through sustained PKA activation. The cAMP analog 8-CPT-cAMP activates both Epac and PKA, which could amplify the functional activity of FOXN2 by increasing its DNA binding affinity or interactions with transcriptional cofactors.
MEK inhibitors like U0126 and PD98059 block the ERK pathway, which phosphorylates FOXO3a, a transcription factor structurally similar to FOXN2. By dampening this pathway, these inhibitors could indirectly enhance FOXN2 activity by reducing phosphorylation-dependent inhibition. PI3K inhibitorssuch as LY294002 and Wortmannin decrease Akt activity, promoting nuclear retention and activity of FOXN2. SP600125 and SB203580 inhibit JNK and p38 MAPK, respectively, potentially reducing competitive inhibition from AP-1 transcription factors and enhancing the availability of transcriptional cofactors for FOXN2. Rapamycin's inhibition of mTOR shifts the balance of protein synthesis, possibly favoring an environment that enhances FOXN2 activity. Chelerythrine and Triciribine inhibit PKC and Akt, respectively, which could decrease inhibitory phosphorylation events, enhancing FOXN2 transcriptional activity by promoting its presence in the nucleus and facilitating transcriptional functions.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin stimulates adenylate cyclase, increasing cAMP levels, which in turn activates PKA. PKA can phosphorylate FOXO1, a transcription factor that shares a similar forkhead domain with FOXN2, potentially enhancing FOXN2 activity by analogous phosphorylation events. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX inhibits phosphodiesterases, maintaining elevated cAMP levels and consequent PKA activation. PKA can then phosphorylate members of the forkhead box family of transcription factors, which may include FOXN2, enhancing its activity. | ||||||
8-CPT-cAMP | 93882-12-3 | sc-201569 sc-201569A | 20 mg 100 mg | $87.00 $316.00 | 19 | |
8-CPT-cAMP is a cAMP analog that activates Epac and PKA. Activation of Epac can result in altered gene expression patterns that increase the functional activity of transcription factors like FOXN2 by enhancing their DNA binding affinity or interaction with cofactors. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that can prevent the phosphorylation of c-Jun, a component of the AP-1 transcription factor complex. By inhibiting JNK, FOXN2 may experience increased activity due to reduced competition for cofactors or DNA binding sites shared with AP-1. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that can indirectly enhance FOXN2 activity by reducing the phosphorylation of competing transcription factors, potentially increasing the availability of cofactors necessary for FOXN2's transcriptional activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an MEK inhibitor that blocks the activation of ERK1/2, reducing phosphorylation of transcription factors that may sequester cofactors or otherwise inhibit FOXN2. This can lead to an enhancement of FOXN2's functional activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which can lead to a decrease in the phosphorylation of S6K1 and 4E-BP1, affecting protein translation. This shift in the cellular environment could create conditions that favor FOXN2's activity, such as by altering the protein synthesis of regulatory cofactors. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor, which decreases Akt phosphorylation. Reduced Akt activity can enhance the activity of FOXN2 by promoting its nuclear localization and decreasing its exclusion from the nucleus, where it exerts transcriptional control. | ||||||
Chelerythrine chloride | 3895-92-9 | sc-3547 sc-3547A | 5 mg 25 mg | $90.00 $317.00 | 17 | |
Chelerythrine is a PKC inhibitor that reduces the phosphorylation of PKC substrates. This may enhance FOXN2 activity by decreasing inhibitory phosphorylation of FOXN2 or its cofactors, thus promoting its transcriptional activity. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine is an Akt inhibitor that prevents the phosphorylation of downstream targets, potentially including members of the FOX transcription factor family. Reduced Akt activity may enhance FOXN2 activity by promoting its nuclear retention and transcriptional function. | ||||||